Glyclopyramide

Glyclopyramide

SCHEMBL49354

O=C(NN1CCCC1)NS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.71
CYP3A4 P08684 2/20 0.71
NFKB1 P19838 2/20 0.71
MAPT P10636 2/20 0.71
KDM4E B2RXH2 1/20 0.71
TP53 P04637 1/20 0.71
GLA P06280 1/20 0.71
GAA P10253 1/20 0.71
ALOX12 P18054 1/20 0.71
FLT1 P17948 4/20 0.53
FLT4 P35916 4/20 0.53
KDR P35968 4/20 0.53
LMNA P02545 2/20 0.52
TSHR P16473 2/20 0.52
THRB P10828 1/20 0.52
HTR2A P28223 1/20 0.52
CYP2C19 P33261 1/20 0.52
ADRA1A P35348 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glyclopyramide SCHEMBL15669226 1.00 ALDH1A1 (0.71) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Glypinamide SCHEMBL343885 0.98 ALDH1A1 (0.74) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Tolazamide SCHEMBL34417 0.83 ALDH1A1 (1.00) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Tolazamide SCHEMBL13725632 0.83 ALDH1A1 (1.00) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Tolazamide SCHEMBL2534564 0.82 ALDH1A1 (0.70) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Tolazamide SCHEMBL28562527 0.82 ALDH1A1 (0.97) ALDH1A1CYP3A4NFKB1MAPTKDM4E
SCHEMBL11627200 0.82 MCHR1 (0.59) ALDH1A1CYP3A4NFKB1MAPTKDM4E
SCHEMBL11626350 0.82 MCHR1 (0.59) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Glypinamide SCHEMBL5243890 0.81 ALDH1A1 (0.59) ALDH1A1CYP3A4NFKB1MAPTKDM4E
Acetohexamide SCHEMBL20267964 0.81 ALDH1A1 (0.73) ALDH1A1CYP3A4NFKB1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4361 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684799-A2 ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF TrueBinding, Inc. (US) 2026-01-28 EP claimed
EP-4640701-A2 GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2025-10-29 EP claimed
US-20250325536-A1 THERAPEUTIC USES OF GLP1R AGONISTS VTV THERAPEUTICS LLC (US) 2025-10-23 US claimed
EP-4520343-A2 GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF Janssen Sciences Ireland Unlimited Company (IE) 2025-03-12 EP claimed
EP-3988123-B1 ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS JANSSEN PHARMACEUTICA NV (BE) 2025-02-26 EP claimed
US-20240065979-A1 Protection of Polyunsaturated Fatty Acids, Lipid-Soluble Vitamins, and Lipid-Soluble Medicaments from Oxidation One Idea LLC (US) 2024-02-29 US claimed
EP-4271371-A1 PROTECTION OF POLYUNSATURATED FATTY ACIDS, LIPID-SOLUBLE VITAMINS, AND LIPID-SOLUBLE MEDICAMENTS FROM OXIDATION One Idea LLC (US) 2023-11-08 EP claimed
EP-4232448-A1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2023-08-30 EP claimed
US-11732019-B2 Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors JANSSEN PHARMACEUTICA NV (BE) 2023-08-22 US claimed
WO-2023084320-A1 RECONSTITUTABLE, SINGLE USE ANTIDIABETIC COMPOSITIONS V-ENSURE PHARMA TECHNOLOGIES PRIVATE LIMITED (IN) 2023-05-19 WO claimed
CN-1348369-A Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent SMITHKLINE BEECHAM PLC (GB) 2002-05-08 CN claimed
WO-2002005795-A2 PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS Kéri Pharma Kft. (HU) 2002-01-24 WO claimed
CN-1332638-A Combination comprising beta-agonist and further antidiabetic agent SMITHKLINE BEECHHAM P L C (GB) 2002-01-23 CN claimed
US-6329404-B1 Pharmaceutical composition TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-11 US claimed
US-6303640-B1 ADMINISTERING OXAZOLE OR THIAZOLE DERIVATIVE COMPOUND FOR REDUCING SIDE EFFECTS OF DIABETIC THERAPY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-16 US claimed
US-6211205-B1 ANTIDIABETIC AGENTS THAT ENHANCE INSULIN SECRETION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-03 US claimed
US-6150383-A COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-11-21 US claimed
CN-1264302-A Treatment of diabetes with thiazolidinediones and sulfonylureas SMITHKLINE BEECHAM PLC (GB) 2000-08-23 CN claimed
CN-1263467-A Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor SMITHKLINE BEECHAM PLC (GB) 2000-08-16 CN claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed